Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1001-11. doi: 10.1007/s00259-012-2078-z. Epub 2012 Feb 17.
[(11)C]DASB is currently the most frequently used highly selective radiotracer for visualization and quantification of central SERT. Its use, however, is hampered by the short half-life of (11)C, the moderate cortical test-retest reliability, and the lack of quantifying endogenous serotonin. Labelling with (18)F allows in principle longer acquisition times for kinetic analysis in brain tissue and may provide higher sensitivity. The aim of our study was to firstly use the new highly SERT-selective (18)F-labelled fluoromethyl analogue of (+)-McN5652 ((+)-[(18)F]FMe-McN5652) in humans and to evaluate its potential for SERT quantification.
The PET data from five healthy volunteers (three men, two women, age 39 ± 10 years) coregistered with individual MRI scans were semiquantitatively assessed by volume-of-interest analysis using the software package PMOD. Rate constants and total distribution volumes (V (T)) were calculated using a two-tissue compartment model and arterial input function measurements were corrected for metabolite/plasma data. Standardized uptake region-to-cerebellum ratios as a measure of specific radiotracer accumulation were compared with those of a [(11)C]DASB PET dataset from 21 healthy subjects (10 men, 11 women, age 38 ± 8 years).
The two-tissue compartment model provided adequate fits to the data. Estimates of total distribution volume (V (T)) demonstrated good identifiability based on the coefficients of variation (COV) for the volumes of interest in SERT-rich and cortical areas (COV V (T) <10%). Compared with [(11)C]DASB PET, there was a tendency to lower mean uptake values in (+)-[(18)F]FMe-McN5652 PET; however, the standard deviation was also somewhat lower. Altogether, cerebral (+)-[(18)F]FMe-McN5652 uptake corresponded well with the known SERT distribution in humans.
The results showed that (+)-[(18)F]FMe-McN5652 is also suitable for in vivo quantification of SERT with PET. Because of the long half-life of (18)F, the widespread use within a satellite concept seems feasible.
[(11)C]DASB 目前是最常用于可视化和量化中枢 SERT 的高选择性放射性示踪剂。然而,其使用受到 (11)C 半衰期短、皮质测试 - 再测试可靠性中等以及缺乏量化内源性 5-羟色胺的限制。用 (18)F 标记在原则上允许在脑组织中进行更长时间的动力学分析采集时间,并可能提供更高的灵敏度。我们的研究目的是首先在人类中使用新的高度 SERT 选择性 [(18)F] 标记氟甲基类似物 (+)-McN5652((+)-[(18)F]FMe-McN5652),并评估其用于 SERT 定量的潜力。
将来自五名健康志愿者(三男两女,年龄 39 ± 10 岁)的 PET 数据与个体 MRI 扫描进行配准,使用 PMOD 软件包进行半定量评估。使用双组织室模型计算速率常数和总分布容积(V(T)),并校正动脉输入函数测量值以用于代谢物/血浆数据。作为特异性放射性示踪剂积聚的测量指标的标准化摄取区域与小脑比与 21 名健康受试者的 [(11)C]DASB PET 数据集进行比较(10 名男性,11 名女性,年龄 38 ± 8 岁)。
双组织室模型为数据提供了充分的拟合。基于 SERT 丰富和皮质区域的感兴趣区体积的变异系数(COV),总分布容积(V(T))的估计值显示出良好的可识别性(COV V(T)<10%)。与 [(11)C]DASB PET 相比,(+)-[(18)F]FMe-McN5652 PET 的平均摄取值有降低的趋势;然而,标准差也略低。总之,大脑中的(+)-[(18)F]FMe-McN5652 摄取与人类已知的 SERT 分布非常吻合。
结果表明,(+)-[(18)F]FMe-McN5652 也适合用 PET 进行 SERT 的体内定量。由于 (18)F 的半衰期较长,因此在卫星概念内广泛使用似乎是可行的。